July 21, 2011 (Paris) -- Australian researchers report they're a step closer to developing a simple blood test for the early detection of Alzheimer's disease.
In early testing, the experimental screening tool proved about 85% accurate at determining the amount of Alzheimer's-associated plaque in people's brains.
If the findings can be replicated in large numbers of people, "they may lead to an economical screen that indicates whether a person is in the early stages of, or at risk of developing, Alzheimer's," says researcher Samantha Burnham, PhD, of the Commonwealth Scientific and Industrial Research Organization (CSIRO) in Perth, Australia.
The test may also help doctors decide whether patients with memory loss need more expensive imaging scans to check for the disease, she tells WebMD.
About 5.4 million Americans have Alzheimer's disease, the most common form of dementia.
Current belief holds that amyloid plaque starts to build up in the brain seven to 10 years prior to the decline in cognitive skills that is often the first symptom of Alzheimer's, says Mary Sano, PhD, director of Alzheimer's disease research at Mt. Sinai School of Medicine in New York City.
Imaging scans using positron emission tomography (PET) and magnetic resonance imaging (MRI) can detect plaque and other brain changes indicative of Alzheimer's years before memory and other symptoms of the disorder are evident. But they are costly and impractical for use on a population-wide basis.
Amyloid levels can also be measured in the cerebral spinal fluid, and there "are a lot of data" indicating this approach can accurately predict which patients with mild cognitive impairment will progress to Alzheimer's, Sano tells WebMD. But a spinal tap is "quite an invasive procedure" that most people would prefer to avoid, she notes.
The new blood test, which spots nine proteins whose levels appear to correlate with amyloid levels in the brain, is one of hundreds in development.
What makes this one stand out is that it was validated against PET scans of the brain -- the gold standard -- in a relatively large study, says the Alzheimer's Association's Heather Snyder, PhD.
Still, further validation is needed, and the test needs to be standardized so it offers consistent results from one lab to another, she tells WebMD.
The findings were presented here at the Alzheimer's Association International Conference.